Bold claim: understanding preterm brain injury hinges on a human-made 3D model that reveals how cerebral hemorrhage damages neural stem cells in newborns. In a study published in Advanced Science, researchers map the steps and molecules involved as injuries unfold after a brain bleed.
Magnus Gram, associate professor of biomedicine at Malmö University, emphasizes the significance: “We have built a model that lets us observe how these injuries develop after cerebral hemorrhage and identify the mechanisms and molecules that drive the process.” This work represents a crucial step toward developing treatments that could help affected children.
Every year, roughly 15 million babies are born prematurely worldwide, making preterm birth the leading cause of neonatal mortality and morbidity. Cerebral hemorrhage affects up to 20% of extremely preterm infants (born before 28 weeks). When these bleeds are severe, the risk of cerebral palsy and other neurological impairments rises, and in the worst cases, life-threatening damage or extensive brain injury with motor and cognitive deficits can occur.
The team’s 3D model successfully recreates the vulnerable subventricular zone (SVZ), a critical brain region near the ventricles filled with cerebrospinal fluid that links brain signaling with blood flow. The SVZ harbors immature blood vessels that are exceptionally fragile; rupture allows blood to flood the ventricles, causing intraventricular hemorrhage (IVH). The SVZ is also a key birthplace for new neurons, so cerebral hemorrhage disrupts neural stem cells, largely because toxic breakdown products from blood leak out and harm substantial portions of the developing brain.
Previous approaches relied on analyzing cerebrospinal fluid or blood from preterm infants or using animal models in which bleeding is artificially induced. Both have notable limitations. The advantage of the new human-cell-based model is twofold: it uses human cells and is reproducible, while offering flexible manipulation of various factors—something harder to achieve in animal systems.
Gram notes that the model’s advantage lies in its human relevance and controllability. He collaborated with investigators from Lund University, Karolinska Institutet, and the KTH Royal Institute of Technology. Anna Herland, a professor at AIMES (the AIMES research center at KTH and Karolinska Institutet), highlights the practical importance: “Seeing relevant responses in both the simulated environment and patient samples is crucial, especially since there is currently no established treatment for these patients.”
Related coverage includes studies on lingering brain symptoms in Long COVID linked to gas exchange in the lungs, a framework for five broad phases of brain structure across a lifetime, and research showing that focused ultrasound combined with chemotherapy may extend survival in certain brain cancers.
In summary, this human 3D model offers a more accurate platform to study how intraventricular bleeding disrupts neural development in preterm infants and to identify interventions that could prevent or lessen long-term neurological damage. The findings prompt important questions: How soon might targeted therapies emerge from this model, and what ethical considerations accompany the translation of such research to clinical trials in vulnerable newborns? Share your thoughts on whether this represents a pivotal turning point or an early step in a longer journey toward effective treatments.
